key: cord-0952055-nflslz3c authors: Falces‐Romero, I; Ruiz‐Bastián, M; Díaz‐Pollán, B; Maseda, E; García‐Rodríguez, J title: Isolation of Aspergillus spp. in respiratory samples of patients with COVID‐19 in a Spanish tertiary care hospital date: 2020-08-04 journal: Mycoses DOI: 10.1111/myc.13155 sha: 81343c63c8592ff89c5fac579461514b8d38310b doc_id: 952055 cord_uid: nflslz3c BACKGROUND: Invasive pulmonary aspergillosis (IPA) is a complication of respiratory bacterial and viral infections such as coronavirus disease 2019 (COVID‐19). PATIENTS/METHODS: In University Hospital La Paz (Madrid, Spain), we reviewed the clinical and demographic characteristics of 10 patients with positive severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) PCR and Aspergillus spp. isolate in respiratory samples. We also recovered results of galactomannan tests in serum and/or bronchoalveolar lavage (BAL) samples. RESULTS: Eight male and two female from 51 to 76 years were recovered. They had reported risk factors to develop IPA (hematological malignancies, immunosuppression, diabetes, obesity, intensive care unit stay, among others). Azole susceptible Aspergillus fumigatus was isolated in nine patients and Aspergillus nidulans was isolated in one patient. Only one case was classified as probable aspergillosis, seven cases as putative aspergillosis, and two cases were not classifiable. Eight patients received antifungal treatment. Seven patients died (70%), two are still inpatient due to nosocomial infections and one was discharged referred to another institution. CONCLUSIONS: This clinical entity has high mortality and therefore it should be performed surveillance with early galactomannan tests and cultures in respiratory samples in order to improve the outcome of the patients with this condition. Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has emerged from Wuhan City (Hubei, China) and has become pandemic across the world (1) . This infection can cause severe respiratory disease with important rate of intensive care unit (ICU) admissions (2) . Bacterial and fungal infections are complications of this viral pneumonia (3, 4) due to the severe damage of lung tissue, cytokine storm and immune-paralysis caused by viral infection-induced acute respiratory distress syndrome (ARDS) (1, 5) . Invasive pulmonary aspergillosis (IPA) has been reported in other respiratory virus such as Influenza viruses (6) . In this case, risk factors are hematological malignancies, solid transplant recipients, ICU stay, diabetes, chronic obstructive pulmonary disease (COPD), systemic corticosteroid administration or chronic kidney disease, among others This article is protected by copyright. All rights reserved (5, 7) . It is essential to study if these factors or similar are related to the risk of developing COVID-19 associated pulmonary aspergillosis (CAPA), as well as to clarify clinical significance of isolation of Aspergillus spp. in respiratory samples in these patients. The aim of this study was to review the isolates of Aspergillus spp. from respiratory samples of patients with COVID-19 during the three months of maximum incidence of COVID-19 in the University Hospital La Paz in Madrid, Spain. We performed a retrospective observational study of patients with positive PCR for SARS-CoV-2 and isolation of Aspergillus spp. in respiratory samples in the same episode during three months (March-May 2020) in University Hospital La Paz (Madrid, Spain), our tertiary care center with 1286 beds. In these three months, we had a total of around 5,700 patients with positive SARS-CoV-2 PCR in the hospital (including our healthcare workers). All demographic, clinical and microbiological data were recovered from the clinical records of the patients. Ten patients, eight male and two female with positive SARS-CoV-2 PCR and Aspergillus spp. isolates in respiratory samples were recovered (age range 51-76 years, median age 69.5 years old). The patients had classic risk factors to develop pulmonary aspergillosis, such as diabetes, obesity, COPD, male sex and old age (≥65 years old). In four patients, the immunosuppressed underlying condition was due to hematological diseases, HIV and ankylosing spondylitis HLA B27+ under treatment with golimumab. Seven patients had an ICU stay with mechanical ventilation and all patients received corticosteroids with different administration routes as part of the anti-COVID-19 treatment ( Table 1) . PCR for SARS-CoV-2 diagnosis was performed in nine patients in samples from nasopharyngeal swab and in the other patient, PCR was performed in BAS. In four patients PCR was performed before hospital stay (days -3 to -1, in Emergency Department), in two patients at the moment of ICU admission (day 0) and in four remaining patients several days after hospital stay (day +2 to +35) ( Table 1) . After the COVID-19 diagnosis, Aspergillus spp. isolates grew on culture media from deep respiratory samples: eight BAS (time range after positive PCR: 2-46 days, median days: 13 days), one sputum (day +11 after positive PCR) and one BAL (day +9 after positive PCR). In two patients the isolate grew on two and five consecutive BAS cultures respectively (Table 1) . Aspergillus fumigatus was isolated in nine patients and Aspergillus nidulans in one patient. Susceptibility to antifungal agents was performed in seven strains (Table 1 ). All tested antifungals showed good in vitro activity in A. fumigatus strains and in the case of A. nidulans, only amphotericin B did not show good activity (MIC=2 g/mL). Galactomannan assays were performed in only three patients, one with positive values in serum (1.97) and BAL (3.87) and another with positive values in two consecutives BAL samples (2.16, 1.11). The third patient had a negative galactomannan test in serum (0.22). Nine patients underwent imaging procedures by chest X-ray or radiographs and only in one patient chest computerized tomography (CT Scan) was employed. In seven cases, it was observed bilateral basal or interstitial infiltrates and in five patients there were present ground-glass opacities. Clinically, cough, fever, dyspnea and/or respiratory insufficiency was observed in nine patients. Only one case was classified as probable aspergillosis, seven cases as putative aspergillosis, and two cases were not classifiable. This article is protected by copyright. All rights reserved To treat COVID-19 infection, all patients received hydroxychloroquine, four patients received tocilizumab and four patients received lopinavir/ritonavir. Eight patients received different intravenous antifungal therapies (four sequential and one combined treatments) due to the isolation of Aspergillus spp. (Table 1) . Final outcome was seven deaths, two prolonged ICU hospitalizations and only one hospital discharge (the patient was referred to other hospital and survived). Fungal infections associated to COVID-19 have been reported since the pandemic originated, especially in ICU stay patients (1-7) and similarly to secondary infections associated to Influenza viruses. Most of the risk factors previously mentioned for IPA are common in both virus (6) . In our series, four out of ten patients had an immunosuppression due to hematological malignancies and/or after receiving immunosuppressive therapy. According to EORTC/MSG criteria (9), there was only one case classified as probable IPA (imaging procedure was done by CT) and according to AspICU algorithm (10) there were seven cases classified as putative IPA and the two remaining cases were not able to be classified by neither algorithm because of lack of ICU stay (criterion of Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zheijiang, China: a retrospective case series COVID-19 associated pulmonary aspergillosis COVID-19 associated pulmonary aspergillosis Bacterial and fungal infections in COVID-19 patients: A matter of concern Fatal invasive aspergillosis and coronavirus disease in a immunocompetent patient Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment Invasive pulmonary aspergillosis complicating COVID-19 in the ICU -A case report Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method Revision and update of the consensus definitions of This article is protected by copyright. All rights reserved